Subthreshold Micro-Pulse Yellow Laser and Eplerenone Drug Therapy in Chronic Central Serous Chorio-Retinopathy Patients: A Comparative Study

Vignesh, T P; Maitray, Aditya; Sen, Sagnik; Chakrabarti, Arup; Kannan, Naresh Babu; Ramasamy, Kim

doi:10.1080/08820538.2020.1809682

Cited by 8 publications

(7 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vignesh et al retrospectively evaluated 48 eyes over a median follow-up of 8 months in YSL and 4.5 months in the eplerenone treatment arm [ 111 ]. Complete SRF resorption was observed in 12/28 (42.8%) eyes in YSML, a much higher proportion compared to eplerenone (4/20, 20%).…”

Section: Clinical Applicationsmentioning

confidence: 99%

Yellow Subthreshold Micropulse Laser in Retinal Diseases: An In-Depth Analysis and Review of the Literature

et al. 2023

View full text Add to dashboard Cite

Yellow subthreshold micropulse laser (YSML) is a retinal laser capable of inducing a biologic response without causing thermal damage to the targeted tissue. The 577-nm YSML is delivered to the retina abiding by different protocols in which wavelength, power, duration, spot size and number of spots can be properly set to achieve the most effective and safe treatment response in various chorioretinal disorders. The ultrashort trains of power modulate the activation of the retinal pigment epithelium cells and intraretinal cells, such as Müller cells, causing no visible retinal scars. Subthreshold energy delivered by YSML stimulates the production of the heat-shock proteins, highly conserved molecules that protect cells against any sort of stress by blocking apoptotic and inflammatory pathways that cause cell damage. YSML treatment allows resorption of the subretinal fluid in central serous chorioretinopathy and intraretinal fluid in various conditions including diabetic macular edema, postoperative cystoid macular edema and other miscellaneous conditions. YSML also seems to modulate the development and progression of reticular pseudodrusen in dry age-related macular degeneration. The aim of this review is to discuss and summarize the safety and efficacy of YSML treatment in retinal diseases.

show abstract

Section: Clinical Applicationsmentioning

confidence: 99%

Yellow Subthreshold Micropulse Laser in Retinal Diseases: An In-Depth Analysis and Review of the Literature

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Previous comparative studies were also conducted to evaluate the efficacy of SML compared to PDT, anti vascular endothelial growth factor (VEGF) treatment or eplerenone 18 , 40 – 47 .…”

Section: Discussionmentioning

confidence: 99%

“…Vignesh et al compared the outcomes of SML and eplerenone treatments in cCSC eyes during a mean follow up of 8 months and reported comparable visual outcomes between the two treatments with 42.8% and 20% of complete resolution of SRF in SML group and eplerenone group respectively 18 .…”

Section: Discussionmentioning

confidence: 99%

“…The effect of different treatments for CSC in the several clinical studies varies according to different CSC-related ocular features and laser parameters 18 , 25 – 47 .…”

Section: Discussionmentioning

confidence: 99%

“…Subthreshold microsecond pulse laser (SML) has been proposed as an effective method to treat cCSC 6 , 12 – 18 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Short-term comparison between navigated subthreshold microsecond pulse laser and oral eplerenone for chronic central serous chorioretinopathy

Toto

D’Aloisio

Nicola

et al. 2022

Sci Rep

View full text Add to dashboard Cite

To compare the anatomical/functional changes after navigated subthreshold pulse laser (SML) and oral eplerenone therapy for chronic central serous chorioretinopathy (cCSC). A total of 36 eyes of 36 patients suffering from cCSC treated with navigated SML (Navilas® 577s; OD-OS GmbH, near Berlin, Germany) (18 eyes, SML group) and oral eplerenone (18 eyes, eplerenone group) were enrolled in this retrospective study. Main outcome measures during a 3-month follow up period included changes of best corrected visual acuity (BCVA), central macular thickness (CMT), foveal subretinal fluid thickness (FSRFT), and subfoveal choroidal thickness (SFCT). At baseline average duration of symptoms was 6.8 ± 0.6 months in SML group and 6.4 ± 0.9 months in eplerenone group (p = 0.127). Mean BCVA, CMT and FSRFT changed significantly over time (p < 0.001). From baseline to 90 days the BCVA improved from 0.3 ± 0.1 to 0.1 ± 0.1 logMAR in SML group and from 0.3 ± 0. to 0.2 ± 0.1 logMAR in eplerenone group, CMT reduced from 357.1 ± 104.3 to 210.6 ± 46.7 μm and from 428.7 ± 107.7 to 332.5 ± 27.5 μm in SML group and eplerenone group respectively, FSRFT reduced from 144.4 ± 108.2 to 22.6 ± 37.2 μm and from 217.1 ± 105.9 to 54.4 ± 86.2 μm in SML group and eplerenone group. 55.6% of patients in SML group and 66.7% in eplerenone group showed a complete resolution of FSRFT during follow up. The interaction between group and time was statistically significant with greater absolute variation for CMT and FSRFT in SML group compared to eplerenone group (p < 0.001 and p = 0.043). SFCT did not change significantly during follow up (p = 0.083) for both groups. Both navigated SML and oral eplerenone were effective treatments showing recovery of retinal morphology and related visual acuity improvement in cCSC.

show abstract

Micropulse Laser versus Eplerenone for Chronic Central Serous Chorioretinopathy: A 12-Month Comparison

Viggiano,

Boscia,

Borrelli

et al. 2024

Ophthalmol Ther

View full text Add to dashboard Cite

Subthreshold Micro-Pulse Yellow Laser and Eplerenone Drug Therapy in Chronic Central Serous Chorio-Retinopathy Patients: A Comparative Study

Cited by 8 publications

References 40 publications

Yellow Subthreshold Micropulse Laser in Retinal Diseases: An In-Depth Analysis and Review of the Literature

Yellow Subthreshold Micropulse Laser in Retinal Diseases: An In-Depth Analysis and Review of the Literature

Short-term comparison between navigated subthreshold microsecond pulse laser and oral eplerenone for chronic central serous chorioretinopathy

Micropulse Laser versus Eplerenone for Chronic Central Serous Chorioretinopathy: A 12-Month Comparison

Contact Info

Product

Resources

About